255 results on '"Hanna, Nawar"'
Search Results
2. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
3. Factors Influencing Prostate Specific Antigen Testing in the United States
4. Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis
5. Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA
6. Combination MRI-targeted and systematic prostate biopsy may overestimate gleason grade on final surgical pathology and impact risk stratification
7. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
8. FG has no added value in prediction of mortality after partial and radical nephrectomy for chromophobe renal cell carcinoma patients
9. Endobronchial Ultrasonography Added to Endoscopic Ultrasonography Improves Staging in Esophageal Cancer
10. A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma
11. Comparative effectiveness of robot-assisted vs. open radical cystectomy
12. Assessment of Cancer Control Outcomes in Patients With High-risk Renal Cell Carcinoma Treated With Partial Nephrectomy
13. THE BURDEN OF UNCONTROLLED CARDIOVASCULAR RISK FACTORS IN MEN WITH PROSTATE CANCER: A RADICAL PC ANALYSIS
14. SLING PROCEDURES FOR FEMALE STRESS INCONTINENCE: DOES SURGICAL SPECIALTY MATTER?: MP65-20
15. RACIAL DISPARITIES IN QUALITY METRICS OF MUSCLE INVASIVE BLADDER CANCER: MP63-06
16. INFORMED DECISION-MAKING FOR PROSTATE-SPECIFIC ANTIGEN SCREENING: MP37-02
17. THE IMPACT OF MEDICARE ELIGIBILITY ON PROSTATE CANCER SCREENING BEHAVIORS: MP21-10
18. CYTOREDUCTIVE NEPHRECTOMY IN THE TARGETED THERAPY ERA: AN ANALYSIS OF THE NATIONAL CANCER DATA BASE: PD04-06
19. TRENDS IN TREATMENT STRATEGIES FOR METASTATIC RENAL CELL CARCINOMA: MP03-15
20. THE POTENTIAL IMPACT OF NEOADJUVANT CHEMOTHERAPY ON PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR NON-UROTHELIAL MUSCLE INVASIVE BLADDER CANCER: MP01-18
21. ONCOLOGIC AND PERIOPERATIVE OUTCOMES OF “CYTOREDUCTIVE” RADICAL CYSTECTOMY FOR PATIENTS WITH METASTATIC BLADDER CANCER IN THE UNITED STATES: MP01-04
22. Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer – Abridged version
23. THE IMPORTANCE OF OTHER CAUSE MORTALITY AND CARDIOVASCULAR MORBIDITY IN PATIENTS WITH METASTATIC PROSTATE CANCER EXPOSED TO CONVENTIONAL ANDROGEN DEPRIVATION THERAPY: MP78-07
24. PATTERNS OF USE OF BONE TARGETED THERAPY IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER PATIENTS: A POPULATION BASED STUDY: MP70-09
25. NEOADJUVANT CHEMOTHERAPY IS NOT ASSOCIATED WITH WORSE SHORT-TERM OUTCOMES IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER UNDERGOING RADICAL CYSTECTOMY: A POPULATION-BASED STUDY: MP61-06
26. SUBOPTIMAL USE OF NEOADJUVANT OR ADJUVANT CHEMOTHERAPY IN RADICAL CYSTECTOMY PATIENTS: A POPULATION-BASED STUDY: MP60-17
27. 90-DAY MORTALITY REPRESENTS A MORE REALISTIC ENDPOINT THAN 30-DAY MORTALITY AFTER RADICAL CYSTECTOMY: MP60-11
28. COMPARATIVE EFFECTIVENESS OF RADICAL CYSTECTOMY VERSUS BLADDER-SPARING TREATMENT FOR MUSCLE-INVASIVE UROTHELIAL CARCINOMA: A POPULATION-BASED REPORT.: MP50-09
29. COMPARATIVE EFFECTIVENESS OF ROBOTIC-ASSISTED VERSUS OPEN RADICAL PROSTATECTOMY CANCER CONTROL OUTCOMES: MP37-07
30. SURVIVAL BENEFIT OF RADICAL PROSTATECTOMY IN PATIENTS WITH CLINICALLY ADVANCED PROSTATE CANCER: ESTIMATIONS OF THE NUMBER NEEDED TO TREAT BASED ON COMPETING-RISKS ANALYSIS: PD12-11
31. DEVELOPMENT AND EXTERNAL VALIDATION OF A PROGNOSTIC TOOL FOR PREDICTION OF CANCER-SPECIFIC MORTALITY AFTER COMPLETE LOCO-REGIONAL PATHOLOGICAL STAGING FOR SQUAMOUS CELL CARCINOMA OF THE PENIS: MP10-19
32. THE BURDEN OF UNCONTROLLED CARDIOVASCULAR RISK FACTORS IN MEN WITH PROSTATE CANCER: A RADICAL PC ANALYSIS
33. CONDITIONAL SURVIVAL OF PATIENTS WITH RENAL CELL CARCINOMA TREATED WITH NEPHRECTOMY: A POPULATION BASED ANALYSIS: 1836
34. Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged ≥75 years with multiple comorbidities
35. A NON-CANCER RELATED SURVIVAL BENEFIT IS ASSOCIATED WITH PARTIAL NEPHRECTOMY: 1681
36. INCREASING RATES OF ACTIVE SURVEILLANCE RELATIVE TO SURGICAL MANAGEMENT IN PATIENTS DIAGNOSED WITH T1AN0M0 RENAL CELL CARCINOMA: 1686
37. PARTIAL NEPHRECTOMY IS NOT ASSOCIATED WITH AN OTHER-CAUSE MORTALITY BENEFIT IN PATIENTS AGED ≥75 YEARS AND/OR MULTIPLE COMORBIDITIES WITH SMALL RENAL MASSES: 1678
38. Local tumor destruction in renal cell carcinoma—An inpatient population-based study
39. Multiparametric Magnetic Resonance Imaging-Ultrasound Fusion Biopsy Improves but Does Not Replace Standard Template Biopsy for the Detection of Prostate Cancer
40. MP49-09 ADJUVANT CHEMOTHERAPY IN THE TREATMENT OF LYMPH NODE POSITIVE SQUAMOUS CELL CARCINOMA OF THE PENIS: ANALYSIS OF THE NATIONAL CANCER DATA BASE
41. Concordance of systematic and fusion biopsy with surgical pathology.
42. Contemporary perceptions of human papillomavirus and penile cancer: Perspectives from a national survey
43. Comparaison populationnelle des résultats périopératoires entre la néphro-urétérectomie ouverte et laparoscopique aux États-Unis
44. Resident involvement in radical inguinal orchiectomy for testicular cancer does not adversely impact perioperative outcomes
45. Adverse effects of androgen deprivation therapy on cognitive impairment for men with prostate cancer: A meta-analysis.
46. Reply to C. Buttigliero et al and B. Biswas et al
47. MP71-09 EFFECTIVENESS OF ADJUVANT CHEMOTHERAPY AFTER RADICAL NEPHROURETERECTOMY FOR LOCALLY ADVANCED AND/OR POSITIVE REGIONAL LYMPH NODE UPPER TRACT UROTHELIAL CARCINOMA
48. MP38-19 MULTIPARAMETRIC MRI/ULTRASOUND FUSION BIOPSY IMPROVES BUT DOES NOT REPLACE STANDARD TEMPLATE BIOPSY FOR THE DETECTION OF PROSTATE CANCER
49. MP22-04 RACIAL DISPARITIES IN THE TREATMENT AND SURVIVAL OF METASTATIC RENAL CELL CARCINOMA
50. PD67-09 COMPARATIVE EFFECTIVNESS OF ROBOT-ASSISTED VS. OPEN RADICAL CYSTECTOMY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.